Targeting epidermal growth factor receptor signaling: Early results and future trends in oncology

Annals of Medicine

Volumn 35, Issue 5, 2003, Pages 327-336

  Lage, Agustín ^a   Crombet, Tania ^a   González, Gisela ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer therapy; Cancer vaccines; Clinical trials; Epidermal growth factor; Epidermal growth factor receptor; Monoclonal antibodies; Tyrosine kinases

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CIMAHER; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; HER 2 VACCINE; HR 3; IMATINIB; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGG1; NIMOTUZUMAB; OSI 744; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; RECOMBINANT EPIDERMAL GROWTH FACTOR; ROSCOVITINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ACNE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARDIOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FEVER; FLU LIKE SYNDROME; GENE ACTIVITY; GENE OVEREXPRESSION; HEAD CANCER; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; NECK CANCER; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; RASH; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0041386348     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Druker BJ. ST1571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 2002; 8 (Suppl): 514-8.
2. Herrara R, Sebolt-Leopold JS. Unravelling the complexities of the Raf/ MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002; 8 (Suppl): 527-31.
3. Sausville EA. Complexities in the development of cyclin-dependent kinase-inhibitor drugs. Trends Mol Med 2002; 8 (Suppl): 532-7.
4. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99.
5. Hanahan D, Weinberg R.A. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
7. Marshall E. Cancer therapy. Set backs for endostatin. Science 2002; 295: 2198-9.
8. Hoekstra R, Eskens FALM, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6: 415-427.
9. Prenzel N, Fisher OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-31.
10. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32-40.
11. Herbst RS, Shing DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2002; 94: 1593-1611.
12. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1s-13s.
13. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal. J Biol Chem 1962; 237: 1555-62.
14. Cohen S, Ushiro H, Stocheck C, Chinkers M.A. A native 170000 epidermal growth factor receptor-kinase complex from shed membrane vesicles. J Biol Chem 1982; 257: 1523-31.
15. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
16. Carpenter G, Cohen S. Epidermal growth factor. Ann Rev Biochem 1979; 48: 193-216.
17. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
18. Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 1984; 44: 3448-53.
19. Perez R, Pascual MR, Macias A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 1984; 4: 189-93.
20. Slamon DJ, Godolphin W, Jones L, Holt J, Wong S, Keith D, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
21. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for the role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13: 1133-7.
22. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996; 73: 301-6.
23. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-60.
24. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF alpha and EGFR protein in head and neck squamous cell lung carcinomas and patient survival. J Natl Cancer Inst 1998; 90: 824-32.
25. Rios MA, Macias A, Perez R, Lage A, Skoog L. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 1988; 8: 173-6.
26. Macias A, Azavedo E, Perez R, Rutquist LE, Skoog L. Receptors for epidermal growth factor in human carcinomas and their metastases. Anticancer Res 1986; 6: 849-52.
27. Macias A, Azavedo E, Hagerstrom T, Klintenberg C, Perez R, Skoog L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinoma. Anticancer Res 1987; 7: 459-64.
28. Downward J, Yarden Y, Mayes E, Scrace G, Toffy N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erbB oncogen protein sequences. Nature 1884; 307: 521-7.
29. Schessinger J. Cell Signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
30. Brandt R, Eisenbrandt R, Leenders F, Zschiesche W, Binas B, Juergensen C, et al. Mammary gland specific hEGF receptor transgene expression induce neoplasie and inhibits differentiation. Oncogene 2000; 19: 2129-37.
31. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82: 1991-9.
32. Scheiberg AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-3.
33. De Jong JS, van Diest PJ, van del Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors and their receptors in invasive breast cancer II: Correlation with proliferation and angiogenesis. J Pathol 1998; 184: 53-7.
34. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
35. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-35.
36. Crombet-Ramos T, Rak Janusz, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody. Int J Cancer 2002; 101: 567-75.
37. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-101.
38. Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line A704. Eur J Cancer 1996; 32A: 1977-82.
39. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70: 722-6.
40. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling requiered for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994; 127: 859-66.
41. Ogawa J, Iwazaqui M, Inoue H, Koide S, Shohtsu A. Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin-sensitivity. Cancer 1993; 71: 2204-9.
42. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
43. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JK, et al. Final results from a phase II trial of ZD1839. ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 292a Abs1166.
44. Kris M, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a Abs1188.
45. Giaccone G, Johnson G, Manengold C, Scagliotti GV, Rosell R, Wolf M, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemonaive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002; 13: 2 Abs 4.
46. Johnson D, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZD 1839 (Iressa) in combination with paclitaxel & carboplatin in chemonaive patients with advanced Non-small cell lung cancer: results from a phase III trial clinical trial (INTACT 2). Ann Oncol 2002; 13: 127 Abs 468O.
47. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 310a Abs 1235.
48. Senzer N, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001; 20: 2a Abs 6.
49. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
50. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
51. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-43.
52. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002; 21: 226a Abs 900.
53. Barbara A, Burtness Yi Li, William Flood, Bassam I Mattar, Arlene A Forastiere. Phase III trial comparing cisplatin (C) + placebo (P) to C+anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC).Proc Am Soc Clin Oncol 2002; 21: 226a Abs 901.
54. Saltz L, Rubin M, Hochster H, Simon T, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a Abs 7.
55. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20(18 Suppl): 1S-13S.
56. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the EGF-R: recovery of antagonistic activity. Immunotechnology 1997; 3: 71-81.
57. Crombet T, Osorio M, Cruz T, Figueredo R, Koropatnick J, Reginfo E, et al. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proc Am Soc Clin Oncol 2002; 21: 14a Abs 53.
58. Winquist E, Nabid A, Sicheri D, Gangul P, Venkatesan V, Schneider V, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002; 21: 232a Abs 926.
59. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
60. Schwartz G, Dutcher JP, Vogelzang N, Gollob J, Thompson J, Bukowski RM, et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 2002; 21: 24a Abs 91.
61. Figlin RA, Belldegrun AS, Crawford J, Lohner M, Roskos L, Yang XD, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21: 10a Abs 35.
62. Coutinho A, Hori S, Carvalho T, Caramalho I, Demengeot J. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses. Immunol Rev 2001; 182: 89-98.
63. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 1999; 96: 5340-2.
64. Dissis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheerer MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 1996; 156: 3151-8.
65. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheerer MA, et al. Generation of T-cell immunity to the Her-2/neu protein after active immunization with Her-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-32.
66. Gonzalez G, Sanchez B, Suarez E, Beausoleil I, Perez O, Lastre M, et al. Recognition of self epidermal growth factor (EGF): effect on EGF-biodistribution and tumor growth. Vaccine Res 1996; 5: 233-44.
67. Gonzalez G, Pardo OL, Sanchez B, Garcia JL, Beausoleil I, Marinello P, et al. Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody response and the use of a fusion protein. Vaccine Res 1997; 6: 91-100.
68. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 1998; 9: 431-5.
69. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, et al. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann Oncol 2003; 14: 461-6.
70. Montero E, Amador JF, Perez R, Lage A. Tumor-specific immunotherapy based on dominant models of natural tolerance. Med Hypotheses 2000; 54: 531-6.
71. Cohen I R. Regulation of autoimmune disease: physiological and therapeutic. Immunol Rev 1986; 94: 5-21.
72. Kris M, Azzoli C, Miller V. Epidermal growth factor receptor blockade: targeted therapy for non-small cell lung cancer. ASCO 2002 Educational Book.693-701.
73. Hiroali K. Systems biology; a brief overview. Science 2002, 295: 1662-4.
74. Csete ME, Doyle JC. Reverse engineering of biological complexity. Science 2002; 295: 1664-9.
75. Gonzalez G, Montero E, Leon K, Cohen I, Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmunity Review 2002; 1: 89-95.